Objective:To compare and evaluate the efficacy of new oral anticoagulants(NOACs)versus vitamin K antagonists(VKA)on the development of dementia in patients with artrial fibrillation(AF).Methods:A computerized search of Web of Science,PubMed,Scopus,Cochrane Library,China Biomedical Medical Literature Database(CBM),China Knowledge Network,WanFang,and VIP databases was performed to include relevant study on oral anticoagulant therapy affecting dementia in patients with atrial fibrillation based on the PICOS principle.The search time was up to September 2023,and Meta-analysis was performed using RevMan 5.4 software and R 4.2.3 software.Results:Thirteen papers with a total of 2 187 211 patients with AF were finally included.The results showed that there was a difference in the comparison of the risk of dementia caused by NOACs and VKA(HR=0.88,95%CI 0.82-0.95);there was no significant difference when comparing vascular dementia and Alzheimer's disease;there was no significant difference between the NOACs,and there was a significant difference in the comparison of edoxaban and warfarin(HR=0.36,95%CI 0.11-0.93).Conclusion:NOACs is superior to VKA in preventing the development of dementia in patients with AF,and more clinical trials are needed to confirm this conclusion in the future.
atrial fibrillationdementiaanticoagulantnew oral anticoagulantsvitamin K antagonist
NETL
NSTL
万方数据
